Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bluejay Diagnostics Inc (BJDX)

Bluejay Diagnostics Inc (BJDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,487
  • Shares Outstanding, K 2,688
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,950 K
  • 60-Month Beta 0.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.24
Trade BJDX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.01
  • Most Recent Earnings $-1.78 on 03/28/24
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4703 +16.95%
on 04/16/24
0.8700 -36.78%
on 03/21/24
-0.2850 (-34.13%)
since 03/19/24
3-Month
0.4703 +16.95%
on 04/16/24
0.9668 -43.11%
on 03/08/24
-0.3374 (-38.02%)
since 01/19/24
52-Week
0.4703 +16.95%
on 04/16/24
13.9799 -96.07%
on 07/24/23
-6.5600 (-92.26%)
since 04/19/23

Most Recent Stories

More News
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness  Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company...

BJDX : 0.5500 (-0.60%)
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device...

BJDX : 0.5500 (-0.60%)
Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing Expanded Testing Program Planned for Q1-Q3 2022 Raised $21.6 million...

BJDX : 0.5500 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bluejay Diagnostics Inc. is a late-stage, pre-revenue medical device company. It focused on developing near-patient products for triage, diagnosis and monitoring of disease progression. Bluejay Diagnostics Inc. is based in ACTON, Mass.

See More

Key Turning Points

3rd Resistance Point 0.6167
2nd Resistance Point 0.6033
1st Resistance Point 0.5767
Last Price 0.5500
1st Support Level 0.5367
2nd Support Level 0.5233
3rd Support Level 0.4967

See More

52-Week High 13.9799
Fibonacci 61.8% 8.8192
Fibonacci 50% 7.2251
Fibonacci 38.2% 5.6310
Last Price 0.5500
52-Week Low 0.4703

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar